BridgeBio Pharma (BBIO) Ph2b Demonstrates Robust POC and Safety Data - Jefferies
Tweet Send to a Friend
Jefferies analyst Eun Yang reiterated a Buy rating and $79.00 price target on BridgeBio Pharma (NASDAQ: BBIO) after the companny ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
